Search
China Greenlights World's Premier Oral Targeted Therapy for HER2-Mutated Advanced NSCLC
2025-08-30 /
Read about 0 minute
Author：小编
On August 29, the National Medical Products Administration granted marketing authorization for Zolbetuximab Tablets. This milestone marks the introduction of the world's first and, to date, only approved oral HER2 tyrosine kinase inhibitor. The drug is specifically designed for the treatment of adult patients diagnosed with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) that harbors HER2 activating mutations, who have undergone at least one prior systemic therapy. Clinical trials have underscored the efficacy and safety of Zolbetuximab Tablets, offering a novel therapeutic avenue for these patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
